A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.
Epistemonikos ID: 5735bf089460c2bf569ca009bdf3a9f62c2d6189
First added on: Oct 23, 2026